Trevena CEO to present at the 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 10:00 a.m. EDT in New York.
TRVN: 6.91 (-0.53)
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 02, 5:09PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
EGLE: 8.55 (+0.05), IMDZ: 26.66 (+0.22), TRVN: 6.91 (-0.53), BCRX: 10.62 (-0.09), ARCW: 7.06 (-0.57), ARWR: 6.88 (+0.14), ASPS: 18.07 (+1.32), EGRX: 60.53 (+1.22), DYAX: 28.12 (+0.15), VBFC: 19.86 (-0.12), SQBG: 13.46 (-0.54), RDI: 13.82 (+0.28), DGLY: 13.13 (+0.08), RDIB: 13.04 (-0.36)
Healthcare ratings round up
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 12:23PM CDT
OXGN: 1.49 (-0.02), TRVN: 6.91 (-0.53), ESPR: 100.53 (-2.60), OVAS: 29.85 (-0.24), UHS: 121.07 (+0.12), NLNK: 53.12 (-0.07), RTRX: 24.45 (+0.09), SYK: 96.45 (+1.74)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 11:49AM CDT
TRVN: 6.91 (-0.53), WGO: 20.92 (-0.21), CCSC: 5.36 (-0.04), OTIV: 1.58 (+0.03), DPLO: 34.52 (+0.26), CNAT: 6.31 (-0.15), WGBS: 4.66 (-0.08), HKTV: 7.67 (-0.33), DVD: 2.34 (-0.02), SEDG: 23.81 (+0.13), ENVA: 19.54 (+0.31), SEED: 1.66 (+0.05), RHT: 75.76 (+0.54), SCMP: 21.75 (+0.47), SGNT: 25.43 (-0.29), WRLD: 74.99 (+0.21), VBLT: 4.37 (-0.08), RCON: 1.87 (-0.04), SNDK: 68.48 (+0.56)
Insiders Seeing Green With TRVN At New 52-Week High
MarketNewsVideo.com - Tue Mar 24, 12:11PM CDT
In trading on Tuesday, shares of Trevena Inc touched a new 52-week high of $8.16/share. That's a 114.74% rise, or $4.36 per share from the 52-week low of $3.80 set back on 12/09/2014.
TRVN: 6.91 (-0.53)
Trevena's Q4 2014 Results Conference Call - What We Learned
Scrying Biotech - at Seeking Alpha - Mon Mar 23, 12:14PM CDT
TRVN: 6.91 (-0.53), ACT: 295.22 (+0.69)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.91 (-0.53), MDT: 78.01 (+0.93), CLDX: 28.95 (+1.08), FOMX: 10.94 (-0.02), AMGN: 169.10 (+0.64), AET: 107.95 (-0.41), NKTR: 10.90 (+0.16), CELG: 115.54 (+0.72), HUM: 180.01 (-0.12), CANF: 2.12 (+0.17), ANTM: 152.84 (-0.04), NVO: 56.37 (-0.17), GILD: 104.18 (-1.02), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), CLLS: 31.30 (-0.91), WCG: 82.65 (-0.33), FOLD: 11.97 (-0.35), REGN: 472.63 (+9.41), CUR: 1.96 (-0.04)
Trevena CMO to Present at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference
Business Wire - Wed Mar 18, 3:30PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced David Soergel, M.D., its chief medical officer, will present a company overview at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference on Friday March 20, 2015 at 3:00 p.m. EDT in New York.
TRVN: 6.91 (-0.53)
Trevena's (TRVN) CEO Max Gowen on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 18, 12:46PM CDT
TRVN: 6.91 (-0.53)
Trevena FY14 results
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 7:53AM CDT
TRVN: 6.91 (-0.53)
Trevena reports 4Q loss
Automated Insights - Wed Mar 18, 6:18AM CDT
KING OF PRUSSIA, Pa. (AP) _ Trevena Inc. (TRVN) on Wednesday reported a loss of $13.3 million in its fourth quarter.
TRVN: 6.91 (-0.53)
Trevena beats by $0.07
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 6:03AM CDT
TRVN: 6.91 (-0.53)
Trevena Reports Full Year 2014 Financial Results
Business Wire - Wed Mar 18, 6:00AM CDT
--- Phase 2b BLAST-AHF Trial of TRV027 in Acute Heart Failure Expanded -
TRVN: 6.91 (-0.53)
Trevena Inc: Profitable To You And Disruptive To Everyone Else
Scrying Biotech - at Seeking Alpha - Mon Mar 16, 5:31PM CDT
TRVN: 6.91 (-0.53), ACT: 295.22 (+0.69)
Trevena to Host Conference Call on March 18th to Discuss Full Year 2014 Financial Results
Business Wire - Wed Mar 11, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced that it will host a conference call on Wednesday, March 18, 2015 at 8:30 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2014.
TRVN: 6.91 (-0.53)
Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure
Business Wire - Mon Mar 09, 6:00AM CDT
--- Actavis fully funds expansion of study -
TRVN: 6.91 (-0.53)